ReviewInternational journal of molecular sciences2022
NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06167460 (Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to Tyrosine Kinase Inhibitors in Patients With Advanced Non-small Cell Lung Cancer), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to Tyrosine Kinase Inhibitors in Patients With Advanced Non-small Cell Lung Cancer
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.Future oncology (London, England) · 2026Review
- Perspectives of patients, partners, primary and hospital-based health care professionals on living with advanced cancer and systemic treatment.Journal of cancer survivorship : research and practice · 2026Article
- Pulmonary surfactant protein D reduces lung cancer progression associated with decreased IL-4/STAT6 signaling.NPJ precision oncology · 2026Article
- Molecular Docking and MD Modeling Techniques for the Development of Novel ROS1 Kinase Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Moving past multidisciplinary discussions and Gender-Age-Physiology model: precision medicine through biological phenotyping in interstitial lung disease.Current opinion in pulmonary medicine · 2025Review
- Blurred Boundaries: Rethinking Disease Classifications in Interstitial Lung Disease Using Molecular Signals.American journal of respiratory and critical care medicine · 2025Article
- Immunotherapy in lung cancer brain metastases.NPJ precision oncology · 2025Review
- The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC.Future oncology (London, England) · 2025Review
- Costs of biomarker testing in advanced non-small cell lung cancer: a global study comparing next-generation sequencing and single-gene testing.The journal of pathology. Clinical research · 2025Observational
- Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer.Current oncology (Toronto, Ont.) · 2024Review
- Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000-2021: a population-based cohort study.Translational lung cancer research · 2024Article
- Decoding Molecular Heterogeneity in Idiopathic Pulmonary Fibrosis.American journal of respiratory and critical care medicine · 2024Article
- A scoring model based on bacterial lipopolysaccharide-related genes to predict prognosis in NSCLC.Frontiers in genetics · 2024Article
- Advancing non-small cell lung cancer treatment: the power of combination immunotherapies.Frontiers in immunology · 2024Review
- An Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC).Biomedicines · 2023Article
- Changes in the Histology of Lung Cancer in Northern Italy: Impact on Incidence and Mortality.Cancers · 2023Article
- Prognostic score and sex-specific nomograms to predict survival in resectable lung cancer: A French nationwide study from the Epithor cohort database.The Lancet regional health. Europe · 2023Article
- Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.International journal of molecular sciences · 2023Review
- Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine.Frontiers in oncology · 2023Review
- Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy.EXCLI journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Standard treatment for advanced non-small cell lung cancer (NSCLC) historically consisted of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a revolutionary change in the therapeutic scenario. The identification of oncogenic driver mutations in EGFR, ALK and ROS1 rearrangements identified a subset of patients who largely benefit from targeted agents. However, since the proportion of patients with druggable alterations represents a minority, the discovery of new potential driver mutations is still an urgent clinical need. We provide a comprehensive review of the emerging molecular targets in NSCLC and their applications in the advanced setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.